Consistent responses with guselkumab treatment in Asian and non‐Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2-Reference-Cited by-同舟云学术

Consistent responses with guselkumab treatment in Asian and non‐Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2

Published:2019-10-20 Issue:12 Volume:46 Page:1141-1152
ISSN:0385-2407
Container-title:The Journal of Dermatology
language:en
Short-container-title:J Dermatol

Author:

Reich Kristian¹^ORCID,Song Michael²,Li Shu²,Jiang Jingzhi²,Youn Sang Woong³^ORCID,Tsai Tsen‐Fang⁴^ORCID,Choe Yong Beom⁵,Huang Yu‐Huei⁶,Gordon Kenneth B.⁷

Affiliation:

1. Center for Translational Research in Inflammatory Skin Diseases Institute for Health Services Research in Dermatology and NursingUniversity Medical Center Hamburg-Eppendorf Skinflammation^® Center Hamburg Germany

2. Janssen Research & Development, LLC Spring House Pennsylvania USA

3. Seoul National University College of MedicineSeoul National University Bundang Hospital Seongnam South Korea

4. National Taiwan University Hospital and National Taiwan University College of Medicine Taipei Taiwan

5. Konkuk University School of Medicine Seoul South Korea

6. Chang Gung Memorial Hospital and School of Medicine Chang Gung University Taoyuan City Taiwan

7. Medical College of Wisconsin Milwaukee Wisconsin USA

Funder

Janssen Research and Development

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1346-8138.15109

Reference30 articles.

1. World Health Organization.Global report on psoriasis[Cited 2018 July 05]. Available from URL:http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf 2016.

2. Epidemiology and Medication Trends in Patients with Psoriasis: A Nationwide Population-based Cohort Study from Korea

3. Epidemiology of psoriatic disease and current treatment patterns from 2003 to 2013: A nationwide, population-based observational study in Taiwan

4. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)

5. The Association of Psoriasis with Human Leukocyte Antigens in Korean Population and the Influence of Age of Onset and Sex

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Drug-Free Remission after the End of Phase III Trials of Three Different Anti-IL-23 Inhibitors in Psoriasis;Dermatology and Therapy;2024-07-29

2. Predictors of Psoriasis Area and Severity Index 100 response in Korean patients with moderate-to-severe plaque psoriasis receiving biologics;European Journal of Dermatology;2023-10

3. Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2;Dermatology and Therapy;2023-09-26

4. Efficacy of guselkumab in difficult‐to‐treat psoriasis regions: Data from VOYAGE 1 and VOYAGE 2 Asian subpopulations;The Journal of Dermatology;2023-06-21

5. Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review;Advances in Therapy;2023-06-18